Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
Total Valuation
FibroBiologics, Inc. has a market cap or net worth of $21.12M. The enterprise value is $10.61M.
Market Cap$21.12M
Enterprise Value$10.61M
Share Statistics
FibroBiologics, Inc. has 67,594,720 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding67,594,720
Owned by Insiders9.14%
Owned by Institutions1.47%
Financial Efficiency
FibroBiologics, Inc.’s return on equity (ROE) is -3.03 and return on invested capital (ROIC) is -194.36%.
Return on Equity (ROE)-3.03
Return on Assets (ROA)-1.94
Return on Invested Capital (ROIC)-194.36%
Return on Capital Employed (ROCE)-2.12
Revenue Per Employee0.00
Profits Per Employee-1.43M
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of FibroBiologics, Inc. is ―. FibroBiologics, Inc.’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio1.63
Price to Fair Value1.63
Price to FCF-0.60
Price to Operating Cash Flow-0.85
PEG Ratio-0.02
Income Statement
In the last 12 months, FibroBiologics, Inc. had revenue of 0.00 and earned -18.65M in profits. Earnings per share was -0.42.
Revenue0.00
Gross Profit-832.00K
Operating Income-16.65M
Pretax Income-18.65M
Net Income-18.65M
EBITDA-17.61M
Earnings Per Share (EPS)-0.42
Cash Flow
In the last 12 months, operating cash flow was -16.39M and capital expenditures -262.00K, giving a free cash flow of -16.66M billion.
Operating Cash Flow-16.39M
Free Cash Flow-16.66M
Free Cash Flow per Share-0.25
Dividends & Yields
FibroBiologics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change-68.80%
50-Day Moving Average0.31
200-Day Moving Average0.47
Relative Strength Index (RSI)46.46
Average Volume (3m)978.93K
Important Dates
FibroBiologics, Inc. upcoming earnings date is Apr 6, 2026, After Close (Confirmed).
Last Earnings DateOct 31, 2025
Next Earnings DateApr 6, 2026
Ex-Dividend Date―
Financial Position
FibroBiologics, Inc. as a current ratio of 3.61, with Debt / Equity ratio of 39.15%
Current Ratio3.61
Quick Ratio3.61
Debt to Market Cap0.24
Net Debt to EBITDA0.14
Interest Coverage Ratio-81.61
Taxes
In the past 12 months, FibroBiologics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
FibroBiologics, Inc. EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.45.
EV to Sales0.00
EV to EBITDA-0.43
EV to Free Cash Flow-0.45
EV to Operating Cash Flow-0.46
Balance Sheet
FibroBiologics, Inc. has $4.89M in cash and marketable securities with $2.41M in debt, giving a net cash position of $2.48M billion.
Cash & Marketable Securities$4.89M
Total Debt$2.41M
Net Cash$2.48M
Net Cash Per Share$0.04
Tangible Book Value Per Share$0.14
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for FibroBiologics, Inc. is $2.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.75
Price Target Upside787.10% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast18.47%